X0508 4 2024-07-01 0001830214 Ginkgo Bioworks Holdings, Inc. DNA 0001873507 Dmytruk Mark E. C/O GINKGO BIOWORKS HOLDINGS, INC. 27 DRYDOCK AVENUE BOSTON MA 02210 1 See remarks 0 Class A Common Stock 2024-07-01 4 M 0 65450 A 1050112 D Class A Common Stock 2024-07-01 4 M 0 18125 A 1068237 D Class A Common Stock 2024-07-01 4 M 0 22916 A 1091153 D Class A Common Stock 2024-07-01 4 M 0 1635 A 1092788 D Class A Common Stock 2024-07-02 4 S 0 49162 .326 D 1043626 D Restricted Stock Units 2024-07-01 4 M 0 65450 D Class A Common Stock 65450 516088 D Restricted Stock Units 2024-07-01 4 M 0 18125 D Class A Common Stock 18125 580000 D Restricted Stock Units 2024-07-01 4 M 0 22916 D Class A Common Stock 22916 1008334 D Class B Common Stock 2024-07-01 4 M 0 1635 D Class A Common Stock 1635 623777 D Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock. Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. Represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock and/or restricted stock units. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction. The RSUs vest in 48 equal monthly installments, which began on April 1, 2023. The RSUs vest in 48 equal monthly installments, which began on April 1, 2024. Includes shares of Class B Common Stock that are subject to vesting conditions. Chief Financial Officer /s/ Karen Tepichin, Attorney-in-Fact 2024-07-05